Pull to refresh
Logo
What Changed
Following Why Sign Up
City Therapeutics files for Nasdaq IPO to fund RNAi pipeline

City Therapeutics files for Nasdaq IPO to fund RNAi pipeline

Money Moves

RNA interference biotech founded by Alnylam's former chief closes $230M Nasdaq IPO; shares rose 24% on debut

October 19th, 2026: IPO closes at $230 million gross

Overview

Updated Oct 21

City Therapeutics closed its upsized Nasdaq IPO on October 19, raising $230 million before fees after underwriters bought all 1.67 million extra shares. The Cambridge biotech sold 12.8 million shares at $18 each. Its stock rose about 24% in its October 16 debut.

City also filed a $239.1 million shelf registration shortly after the IPO, setting up possible future share sales. The RNA interference developer, chaired by former Alnylam chief John Maraganore, will use the IPO money to fund three clinical programs and its drug-discovery platform.

Why it matters

City's $230 million IPO tests whether public investors will fund the next generation of RNA interference drugs.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

$230M
Gross IPO proceeds
12.8 million shares at $18, including the full 1.67 million overallotment
$1.0B
Market cap at IPO pricing
Based on the $18 offering price
+24%
First-day stock gain
CTY closed at $22.40 on October 16, its first day on the Nasdaq Global Market
$238.8M
Private capital raised before the IPO
From investors including Arch Venture Partners and Fidelity; Boston Business Journal reports nearly $235 million
$53.4M
Net loss, first half of 2026
Against $6.4 million in collaboration revenue; accumulated deficit of $142.5 million as of June 30, 2026
$239.1M
Shelf registration
Filed after the IPO; covers 13,285,806 shares tied to an employee stock plan

Voices

Curated perspectives — historical figures and your fellow readers.

Sign up to generate historical perspectives on this story.

Log in Sign Up

People Involved

John Maraganore
John Maraganore
Executive Chair, City Therapeutics
Shepherded City through its October 2026 IPO, which closed at $230 million gross after the full overallotment was exercised
AO
Andrew Orth
President and Chief Executive Officer, City Therapeutics
Led City through its October 2026 IPO, which closed at $230 million gross

Organizations Involved

City Therapeutics
City Therapeutics
Clinical-stage biopharmaceutical company
Trading on Nasdaq under CTY after its October 2026 IPO closed at $230 million gross

Developer of RNA interference therapeutics for hepatic and extrahepatic targets.
Arch Venture Partners
Arch Venture Partners
Venture capital firm
Largest shareholder, about 35% pre-IPO

Venture capital firm backing City Therapeutics since its founding.
Goldman Sachs
Goldman Sachs
Investment bank
Lead book-runner on the IPO

Joint book-runner with Jefferies, Stifel, and Oppenheimer.

Timeline

July 2023 October 2026

9 events Latest: October 19th, 2026 · 3 weeks ago
Tap a bar to jump to that date

  1. IPO closes at $230 million gross

    Latest IPO

    City closed its upsized IPO after underwriters exercised their full option for 1.67 million additional shares. The company sold 12.8 million shares at $18 each, for $230.0 million in gross proceeds.

  2. Adopts post-IPO charter

    Filing

    City filed an amended and restated certificate in Delaware authorizing 500 million common shares and 10 million preferred shares. The charter also removed stockholders' ability to act by written consent or call special meetings.

  3. Files $239.1M shelf registration

    Filing

    City filed a $239.1 million shelf registration shortly after its IPO. The filing covers 13,285,806 common shares tied to an employee stock plan, Yahoo Finance reported.

  4. Shares debut on Nasdaq, close up 24%

    Market

    CTY began trading on the Nasdaq Global Market and closed at $22.40, 24% above the $18 IPO price.

  5. IPO priced at $18, upsized to $200 million

    IPO

    City priced 11.1 million shares at $18, up from the 9.72 million planned, raising about $200 million gross. Underwriters hold a 30-day option for 1.67 million more shares.

  6. Amended S-1 sets price range

    Filing

    Amendment sets $17-$19 per share, 9.72 million shares, projected $956 million valuation at top of range.

  7. Initial S-1 filed with SEC

    Filing

    Company files initial IPO registration statement with the Securities and Exchange Commission.

  8. Confidential IPO filing with SEC

    Filing

    City Therapeutics filed its draft registration statement confidentially with the SEC, more than two months before the public S-1. The filing was made public in late September.

  9. City Therapeutics founded

    Founding

    Company launched in Cambridge by John Maraganore and co-founders, with $238.8 million eventually raised privately.

Scenarios

1

City Therapeutics prices its IPO at or near the midpoint

Likely Resolves by Nov 30, 2026

Discussed by: Quartz, MedPharmaNews, and the underwriting syndicate's syndication desk

The offering prices around $18 per share, raising about $175 million gross and roughly $158.3 million in net proceeds. The company lists on the Nasdaq Global Market under CTY, with the overallotment option adding up to 1.46 million more shares if exercised.

2

City Therapeutics cuts its offering size or price

Possible Resolves by Nov 30, 2026

Discussed by: Market analysts tracking the biotech IPO window

If investor demand softens between filing and pricing, City may lower the price range or reduce shares offered below 9.72 million. This happened to several biotech IPOs in 2022, when a cold market forced companies to price at the bottom of ranges or shrink deals.

3

IPO withdrawn or indefinitely delayed

Unlikely Resolves by End of 2026

Discussed by: Observers of biotech IPO market cycles

A sharp market downturn or sudden volatility could push City to pull the offering, as several biotechs did in late 2022 when the IPO window slammed shut. The company would retain its $141.9 million cash cushion and revisit listing later.

4

City shares slide below the $18 IPO price as biotech sector cools

Possible Resolves by End of 2026

Discussed by: Biotech IPO watchers tracking the RNAi space

IPOs often give back first-day gains once the hype fades. City's next catalyst is additional Phase 1 data for CITY-FXI, due late 2026, with a Phase 2 study in total knee arthroplasty set to start in mid-2027.

5

CITY-FXI Phase 1 data pushes shares higher

Possible Resolves by End of 2026

Discussed by: Investors watching the RNAi pipeline (TheBench.Bio)

Early Phase 1 results showed 60% to 85% FXI knockdown after single doses of 15, 50, and 150 mg. Additional data expected late 2026 could move the stock if knockdown and safety hold up.

6

City taps its $239.1 million shelf for a follow-on offering

Possible Resolves by Oct 18, 2027

Discussed by: Yahoo Finance and investors watching City's post-IPO filings

City filed a $239.1 million shelf registration shortly after its IPO, giving it capacity for future stock sales. The filing covers 13,285,806 shares tied to an employee stock plan, but the company has not said whether it will sell more equity or use the shares for grants.

Historical Context

2 moments from history that rhyme with this story — and how they unfolded.

May 2004

Alnylam Pharmaceuticals IPO (2004)

Alnylam went public two years after its founding, before any RNAi drug had been approved. The company spent 14 years navigating development failures and delivery challenges before winning FDA approval for ONPATTRO in 2018, the first RNA interference therapeutic on the market.

Then

The IPO funded early research, but the field's promise took over a decade to prove in patients.

Now

Alnylam validated the RNAi approach and established the GalNAc conjugation technology for liver-targeted delivery that City Therapeutics now uses.

Why this matters now

City's lead candidate CITY-FXI uses the same approach Alnylam pioneered. John Maraganore, who led Alnylam through its own IPO and first approval, now chairs City.

December 2018

Moderna IPO (2018)

Moderna raised more than $600 million in its December 2018 IPO at $23 a share, valuing the company near $7.5 billion despite having no approved products. The offering was a bet on the versatility of its messenger RNA platform.

Then

Critics called the valuation rich for a company with no revenue; shares initially traded below the offering price.

Now

The platform proved out two years later when Moderna's COVID-19 vaccine became one of the most widely used in the world.

Why this matters now

Like Moderna, City is a platform company — its 'City Platform' spans multiple RNAi triggers beyond its lead candidates. The IPO tests whether investors pay for platform optionality, not just near-term products.

Sources

(19)
+13
U.S. Securities and Exchange Commission Quartz MedPharmaNews BioSpace Kalkine 24/7 Wall St. StreetInsider Renaissance Capital IPOScoop City Therapeutics (GlobeNewswire) BioPharma Dive Fierce Biotech Boston Business Journal TheBench.Bio Seeking Alpha Yahoo Finance City Therapeutics U.S. Securities and Exchange Commission U.S. Securities and Exchange Commission